MedTrace Logo

Phase II Iressa Versus Vinorelbine (INVITE)

NCT00256711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2009-04-23

No results posted yet for this study

Summary

This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Gefitinib

DRUG

Vinorelbine

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2006-02-28

Countries

  • Australia
  • Brazil
  • Czechia
  • France
  • Germany
  • Italy
  • South Africa
  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00256711 on ClinicalTrials.gov